Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in CHD and Type 2 Diabetes (EFFORT)
NCT03011775Phase 4Completed
- Sponsor
- Poltava State Medical University
- Start
- Nov 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pioglitazone in coronary heart disease (CHD) and atherosclerosis (2 arms), sponsored by Poltava State Medical University. Primary endpoints: Cardiovascular Death at 1 year, Coronary Revascularization Procedures at 1 year and 2 more. Started Nov 2012; status: completed.
02
Drugs
pioglitazone
03
Conditions
coronary heart disease (CHD)atherosclerosis
Beyond the preview
Go deeper on NCT03011775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011775.